Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial.

Baker JV, Sharma S, Achhra AC, Bernardino JI, Bogner JR, Duprez D, Emery S, Gazzard B, Gordin J, Grandits G, Phillips AN, Schwarze S, Soliman EZ, Spector SA, Tambussi G, Lundgren J; INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group.

J Am Heart Assoc. 2017 May 22;6(5). pii: e004987. doi: 10.1161/JAHA.116.004987.

2.

Implementation of a Simplified Regional Citrate Anticoagulation Protocol for Post-Dilution Continuous Hemofiltration Using a Bicarbonate Buffered, Calcium Containing Replacement Solution.

Kirwan CJ, Hutchison R, Ghabina S, Schwarze S, Beane A, Ramsay S, Thompson E, Prowle JR.

Blood Purif. 2016;42(4):349-355. Epub 2016 Nov 19.

3.

Migratory blackcaps can use their magnetic compass at 5 degrees inclination, but are completely random at 0 degrees inclination.

Schwarze S, Steenken F, Thiele N, Kobylkov D, Lefeldt N, Dreyer D, Schneider NL, Mouritsen H.

Sci Rep. 2016 Sep 26;6:33805. doi: 10.1038/srep33805.

4.

Mutant IDH1 and thrombosis in gliomas.

Unruh D, Schwarze SR, Khoury L, Thomas C, Wu M, Chen L, Chen R, Liu Y, Schwartz MA, Amidei C, Kumthekar P, Benjamin CG, Song K, Dawson C, Rispoli JM, Fatterpekar G, Golfinos JG, Kondziolka D, Karajannis M, Pacione D, Zagzag D, McIntyre T, Snuderl M, Horbinski C.

Acta Neuropathol. 2016 Dec;132(6):917-930. Epub 2016 Sep 23.

PMID:
27664011
5.

Weak Broadband Electromagnetic Fields are More Disruptive to Magnetic Compass Orientation in a Night-Migratory Songbird (Erithacus rubecula) than Strong Narrow-Band Fields.

Schwarze S, Schneider NL, Reichl T, Dreyer D, Lefeldt N, Engels S, Baker N, Hore PJ, Mouritsen H.

Front Behav Neurosci. 2016 Mar 22;10:55. doi: 10.3389/fnbeh.2016.00055. eCollection 2016.

6.

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.

Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group.

J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24.

PMID:
26702926
7.

Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy.

Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre JM, Amieva H, Cabié A, Williams I, Di Perri G, Tellez MJ, Rockstroh J, Babiker A, Pozniak A, Raffi F, Richert L; NEAT 001/Agence Nationale de Recherche sur le SIDA (ANRS) 143 Study Group.

HIV Med. 2016 Jun;17(6):471-8. doi: 10.1111/hiv.12344. Epub 2015 Nov 26.

PMID:
26611175
8.

Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.

Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buño A, Castagna A, Girard PM, Chene G, Raffi F, Arribas JR; NEAT001/ANRS143 Study Group.

Lancet HIV. 2015 Nov;2(11):e464-73. doi: 10.1016/S2352-3018(15)00181-2. Epub 2015 Sep 30.

PMID:
26520926
9.

β-Structure within the Denatured State of the Helical Protein Domain BBL.

Thukral L, Schwarze S, Daidone I, Neuweiler H.

J Mol Biol. 2015 Sep 25;427(19):3166-76. doi: 10.1016/j.jmb.2015.08.007. Epub 2015 Aug 14.

PMID:
26281710
10.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD.

N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.

11.

[Needlestick Injuries to Medical Students].

Siegmann S, Muth T, Kluth W, Hofbauer U, Angerer P, Schwarze S.

Gesundheitswesen. 2016 Jan;78(1):22-7. doi: 10.1055/s-0034-1387716. Epub 2015 Jun 18. German.

PMID:
26086540
12.

Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Geffen N, Aagaard P, Corbelli GM, Meulbroek M, Peavy D, Rappoport C, Schwarze S, Collins S; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Community Advisory Board.

HIV Med. 2015 Apr;16 Suppl 1:10-3. doi: 10.1111/hiv.12228.

13.

Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.

INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD.

HIV Med. 2015 Apr;16 Suppl 1:1-9. doi: 10.1111/hiv.12227. No abstract available.

14.

Microsecond folding and domain motions of a spider silk protein structural switch.

Ries J, Schwarze S, Johnson CM, Neuweiler H.

J Am Chem Soc. 2014 Dec 10;136(49):17136-44. doi: 10.1021/ja508760a. Epub 2014 Nov 25.

PMID:
25382060
15.

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.

Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group.

Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4.

PMID:
25103176
16.

The N-terminal domains of spider silk proteins assemble ultrafast and protected from charge screening.

Schwarze S, Zwettler FU, Johnson CM, Neuweiler H.

Nat Commun. 2013;4:2815. doi: 10.1038/ncomms3815.

PMID:
24240554
17.

Progesterone receptor membrane component 1/Sigma-2 receptor associates with MAP1LC3B and promotes autophagy.

Mir SU, Schwarze SR, Jin L, Zhang J, Friend W, Miriyala S, St Clair D, Craven RJ.

Autophagy. 2013 Oct;9(10):1566-78. doi: 10.4161/auto.25889. Epub 2013 Sep 4.

PMID:
24113030
18.

Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066).

Thoden J, Potthoff A, Bogner JR, Brockmeyer NH, Esser S, Grabmeier-Pfistershammer K, Haas B, Hahn K, Härter G, Hartmann M, Herzmann C, Hutterer J, Jordan AR, Lange C, Mauss S, Meyer-Olson D, Mosthaf F, Oette M, Reuter S, Rieger A, Rosenkranz T, Ruhnke M, Schaaf B, Schwarze S, Stellbrink HJ, Stocker H, Stoehr A, Stoll M, Träder C, Vogel M, Wagner D, Wyen C, Hoffmann C; Deutsche AIDS Gesellschaft; Österreichische AIDS-Gesellschaft.

Infection. 2013 Sep;41 Suppl 2:S91-115. doi: 10.1007/s15010-013-0504-1. Epub 2013 Sep 14.

19.

[Interview with Dr. med. Nazifa Qurishi, Köln, and with Siegfried Schwarze, Berlin. HIV therapy from the viewpoint of a physician and of a patient].

Qurishi N, Schwarze S.

MMW Fortschr Med. 2013 Jun 13;155 Suppl 1:41. German. No abstract available.

PMID:
23961655
20.

[History of 25 years antiretroviral therapy].

Bogner J, Schwarze S.

MMW Fortschr Med. 2013 Jun 13;155 Suppl 1:14-6. German. No abstract available.

PMID:
23961645

Supplemental Content

Loading ...
Support Center